Eventide Healthcare & Life Sciences Fund CLASS N SHARES (ETNHX)
NASDAQ · Mutual Fund
· Delayed Price · Currency is USD
36.95
+0.50 (1.37%)
Oct 18, 2024, 8:00 PM EDT
19.35% (1Y)
| Fund Assets | 1.49B |
| Expense Ratio | 1.51% |
| Min. Investment | $1,000 |
| Turnover | 71.00% |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | n/a |
| Previous Close | 36.45 |
| YTD Return | 0.72% |
| 1-Year Return | 17.73% |
| 5-Year Return | 43.06% |
| 52-Week Low | 27.68 |
| 52-Week High | 39.38 |
| Beta (5Y) | 0.76 |
| Holdings | 95 |
| Inception Date | Dec 27, 2012 |
About ETNHX
Under normal market conditions, the fund invests at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts ("ADRs"). The fund may invest in securities of companies of any market capitalization.
Fund Family Eventide Funds
Category Health
Performance Rating Below Average
Risk Rating High
Stock Exchange NASDAQ
Ticker Symbol ETNHX
Index S&P Biotechnology Select Industry TR
Performance
ETNHX had a total return of 17.73% in the past year. Since the fund's inception, the average annual return has been 13.79%, including dividends.
Top 10 Holdings
31.44% of assets| Name | Symbol | Weight |
|---|---|---|
| Celldex Therapeutics, Inc. | CLDX | 4.01% |
| Mirum Pharmaceuticals, Inc. | MIRM | 4.00% |
| Vaxcyte, Inc. | PCVX | 3.87% |
| Insmed Incorporated | INSM | 3.14% |
| Aura Biosciences, Inc. | AURA | 3.04% |
| Guardant Health, Inc. | GH | 2.91% |
| Collegium Pharmaceutical, Inc. | COLL | 2.87% |
| Axsome Therapeutics, Inc. | AXSM | 2.78% |
| Sarepta Therapeutics, Inc. | SRPT | 2.51% |
| Lexeo Therapeutics, Inc. | LXEO | 2.32% |